PMID- 37522848
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20231103
IS  - 2049-3614 (Print)
IS  - 2049-3614 (Electronic)
IS  - 2049-3614 (Linking)
VI  - 12
IP  - 10
DP  - 2023 Oct 1
TI  - Protective effect of GLP-1 analog liraglutide on podocytes in mice with diabetic 
      nephropathy.
LID - e230284 [pii]
LID - 10.1530/EC-23-0284 [doi]
AB  - Protection of podocytes is one of the important means to delay the progression of 
      diabetic nephropathy (DN), and glucagon-like peptide-1 (GLP-1) has been shown to 
      have a protective effect on the kidney in DN models, but whether it has a 
      protective effect on podocytes and the potential mechanisms of action remain 
      largely unknown. In the present study, we established a type 2 diabetes mellitus 
      (T2DM) mouse model by high-fat diet feeding combined with streptozotocin (STZ) 
      induction and administered the intervention for 14 weeks. We found that 
      liraglutide significantly ameliorated podocyte injury in DN mice. 
      Mechanistically, we detected glucagon-like peptide-1 receptor (GLP-1R) protein 
      expression levels in kidney tissues by immunohistochemical staining, 
      immunofluorescence staining, and western blotting and found that podocytes could 
      express GLP-1R and liraglutide treatment could restore GLP-1R expression in the 
      kidney tissues of DN mice. Furthermore, we found that NLRP3-induced inflammation 
      and pyroptosis were positively correlated with podocyte injury in DN mice, and 
      liraglutide inhibited the expression of NLRP3-induced inflammation and 
      pyroptosis-related proteins. Our results suggest that liraglutide protects DN 
      mouse podocytes by regulating GLP-1R in renal tissues and by regulating 
      NLRP3-induced inflammation and pyroptosis.
FAU - Shi, Shaomin
AU  - Shi S
AUID- ORCID: 0009-0000-7226-3537
AD  - Division of Nephrology, The First Affiliated Hospital of Yangtze University, 
      Jingzhou, China.
FAU - Chen, Xinghua
AU  - Chen X
AD  - Division of Nephrology, Renmin Hospital of Wuhan University, Wuhan, China.
FAU - Yu, Wen
AU  - Yu W
AD  - Department of Immunology, School of Medicine, Yangtze University, Jingzhou, 
      China.
FAU - Ke, Xiaolan
AU  - Ke X
AD  - Division of Nephrology, The First Affiliated Hospital of Yangtze University, 
      Jingzhou, China.
FAU - Ma, Tean
AU  - Ma T
AUID- ORCID: 0009-0004-6949-9126
AD  - Division of Nephrology, The First Affiliated Hospital of Yangtze University, 
      Jingzhou, China.
LA  - eng
PT  - Journal Article
DEP - 20230828
PL  - England
TA  - Endocr Connect
JT  - Endocrine connections
JID - 101598413
PMC - PMC10503227
OTO - NOTNLM
OT  - diabetic nephropathy
OT  - glucagon-like peptide-1 receptor
OT  - liraglutide
OT  - podocytes
OT  - pyroptosis
COIS- The authors declare no conflict of interest.
EDAT- 2023/07/31 13:10
MHDA- 2023/07/31 13:11
PMCR- 2023/08/28
CRDT- 2023/07/31 10:23
PHST- 2023/07/13 00:00 [received]
PHST- 2023/07/31 00:00 [accepted]
PHST- 2023/07/31 13:11 [medline]
PHST- 2023/07/31 13:10 [pubmed]
PHST- 2023/07/31 10:23 [entrez]
PHST- 2023/08/28 00:00 [pmc-release]
AID - e230284 [pii]
AID - EC-23-0284 [pii]
AID - 10.1530/EC-23-0284 [doi]
PST - epublish
SO  - Endocr Connect. 2023 Aug 28;12(10):e230284. doi: 10.1530/EC-23-0284. Print 2023 
      Oct 1.